NorthWest Biotherapeutics Inc (NWBO)

[Gus McCrae]

So to release top line prior to receiving final approval for publication from any journal would be at the very least, risky, and I'd think definitely an action their advisors would have recommended against doing.

I have never heard of any company waiting to release TLD until they had a commitment to publish a journal article. And yet, the full data analysis from clinical trials of significant importance always ends up being published in a journal...

If NWBO is really doing this, this decision would be unprecedented and it makes no sense, strategically or otherwise, to release TLD in this manner. The journal article won't matter to investors (as long as TLD doesn't address whatever negative aspects of the trial an analysis of the full data will reveal) or the FDA (it won't matter to them at all)...it will matter to medical professionals, sure, but that's it. That's why no other company has ever done it this way. And, it's why I think DI is lying or not correcting the narrative that TLD and a journal article are tied together.